Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Renalytix AI Plc (GB:RENX)
LSE:RENX
Holding GB:RENX?
Track your performance easily
RENX Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range7.00p - 74.90p
Previous Close8p
Volume113.66K
Average Volume (3M)207.73K
Market Cap
£26.69M
Enterprise Value29.67M
Total Cash (Recent Filing)$4.68M
Total Debt (Recent Filing)$8.54M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Nov 27, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding333,637,612
10 Day Avg. Volume303,032
30 Day Avg. Volume207,732
Standard Deviation0.43
R-Squared0.03
Alpha-0.00205
Financial Highlights & Ratios
Price to Book (P/B)-88.89
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.82
Enterprise Value/Gross Profit190.17
Enterprise Value/Ebitda-0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renalytix AI News
PremiumCompany Announcements
Renalytix Sees Major Shift in Voting Rights
PremiumCompany Announcements
Renalytix PLC Sees Major Voting Rights Shift
PremiumCompany Announcements
Renalytix Adjusts Share Capital Amid Fundraising Shortfall
PremiumCompany Announcements
Renalytix Sees Major Stake Acquisition by Ruffer LLPPremiumCompany Announcements
Renalytix Appoints Julian Baines as Executive Chairman
PremiumCompany Announcements
Renalytix AI Sees Shift in Voting Rights Control
PremiumCompany Announcements
Renalytix Announces Director Departure Amid Strategic Growth
PremiumCompany Announcements
Renalytix Gains Shareholder Support, Advances DiagnosticsOptions Prices
Currently, No data available
---
Ownership Overview
15.40% Insiders
0.05% Other Institutional Investors
84.55% Public Companies and
Individual Investors
RENX FAQ
What was Renalytix AI Plc’s price range in the past 12 months?
Renalytix AI Plc lowest share price was 7.00p and its highest was 74.90p in the past 12 months.
What is Renalytix AI Plc’s market cap?
Currently, no data Available
When is Renalytix AI Plc’s upcoming earnings report date?
Renalytix AI Plc’s upcoming earnings report date is Nov 27, 2024 which is in 17 days.
How were Renalytix AI Plc’s earnings last quarter?
Renalytix AI Plc released its earnings results on Oct 01, 2024. The company reported -0.012p earnings per share for the quarter, beating the consensus estimate of -0.015p by 0.004p.
Is Renalytix AI Plc overvalued?
According to Wall Street analysts Renalytix AI Plc’s price is currently Overvalued.
Does Renalytix AI Plc pay dividends?
Renalytix AI Plc does not currently pay dividends.
What is Renalytix AI Plc’s EPS estimate?
Renalytix AI Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix AI Plc have?
Renalytix AI Plc has 333,637,600 shares outstanding.
What happened to Renalytix AI Plc’s price movement after its last earnings report?
Renalytix AI Plc reported an EPS of -0.012p in its last earnings report, beating expectations of -0.015p. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Renalytix AI Plc?
Currently, no hedge funds are holding shares in GB:RENX
---
Renalytix AI Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-73.97%
Trailing 12-Months
Company Description
Renalytix AI Plc
Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.
---
RENX Earnings Call
Q3 2024
0:00 / 0:00
---
Technical Analysis
---